Statement of Changes in Beneficial Ownership (4)
February 19 2021 - 5:29PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
OLER ABRAHAM N. |
2. Issuer Name and Ticker or Trading Symbol
Onconova Therapeutics, Inc.
[
ONTX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) SVP Corp Dev & Gen Counsel |
(Last)
(First)
(Middle)
375 PHEASANT RUN |
3. Date of Earliest Transaction
(MM/DD/YYYY)
2/17/2021 |
(Street)
NEWTOWN, PA 18940
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Appreciation Right | $1.51 | 2/17/2021 | | A | | 208000 | | (1) | 2/17/2031 | Common Stock (2) | 208000 | $0 | 208000 | D | |
Explanation of Responses: |
(1) | These stock appreciation rights vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. |
(2) | These stock appreciation rights represent the right to receive a cash payment equal to the excess, if any, of (i) the fair market value of each underlying share of the Company's common stock, determined on the date of exercise minus (ii) the exercise price; provided, that in no event may the cash payment for each stock appreciation right exceed $1.03, which is the maximum price per share of $2.54, minus the base amount of $1.51, subject to adjustment in accordance with the terms of the award agreement. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
OLER ABRAHAM N. 375 PHEASANT RUN NEWTOWN, PA 18940 |
|
| SVP Corp Dev & Gen Counsel |
|
Signatures
|
/s/ Mark Guerin as attorney-in-fact | | 2/19/2021 |
**Signature of Reporting Person | Date |
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Sep 2023 to Sep 2024